MK-677 (Ibutamoren) + Thymosin Alpha-1 Stack: Safety and Monitoring

What Each Compound Actually Is

MK-677 (ibutamoren mesylate) is not a peptide. It is an oral, non-peptide small molecule that stimulates growth hormone release by acting on the ghrelin receptor; Merck first synthesized it in 1995 and development was discontinued in 1999 [5]. It has no FDA approval and is not a component of any FDA-approved drug [5].

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide originally isolated from thymosin fraction 5, a thymus extract. Thymalfasin is the synthetic version with the same sequence, and Zadaxin is the brand of the finished injection sold outside the United States at 1.6 mg per vial [4]. Thymosin alpha-1 has no FDA approval; four US orphan drug designations exist, but orphan designation is a different process from approval [4]. In healthy volunteers it is absorbed quickly after subcutaneous injection, peaking at about 0.7 to 2 hours with a half-life of about 1.8 to 2.6 hours [4].

MK-677: The Documented Safety Problems

Congestive heart failure and fluid overload

FDA lists ibutamoren mesylate among bulk substances that raise significant safety risks for compounding, and gives its reason as 'the potential for congestive heart failure in certain patients', citing a hip-fracture trial 'terminated early due to a potential safety signal of congestive heart failure' [1].

That trial enrolled 123 patients aged 60 or older recovering from hip fracture, randomized to MK-677 25 mg daily (n=62) or placebo (n=61) for 24 weeks. Per FDA's summary, 4 patients (6.5%) on MK-677 developed congestive heart failure versus 1 (1.7%) on placebo, systolic blood pressure rose 11.9 to 16.4 mmHg versus 2.3 to minus 2.3 on placebo, and serious adverse events occurred in 24% versus 13%. The authors concluded that MK-0677 'has an unfavorable safety profile' in this population [2][5].

A second hip-fracture trial, 161 patients aged 65 or older on 25 mg daily for 6 months, recorded edema or fluid overload in 16 patients on MK-677 versus 10 on placebo, and thrombosis in 4 versus 0 [6][5]. FDA's September 2025 consumer warning about a children's product containing undisclosed ibutamoren lists water retention and changes in glucose metabolism among the risks and says the ingredient 'may increase the potential for congestive heart failure in certain individuals' [7].

Blood glucose and HbA1c

Glucose rose in several adult trials. In 65 healthy adults aged 60 to 81 taking 25 mg daily for 12 months, fasting glucose rose by about 5 mg/dL (P=0.015) and insulin sensitivity fell; body weight rose 2.7 kg versus 0.8 kg on placebo [3][5]. In the 161-patient hip-fracture trial, glucose rose 8.0 mg/dL versus a 1.6 mg/dL fall on placebo, and HbA1c rose 0.7% versus 0.3% [6][5]. In 563 patients with mild to moderate Alzheimer's disease treated for 12 months, blood glucose increases occurred in 15.4% versus 4.6% on placebo and HbA1c increases in 11.1% versus 1.4% [8][5]. In 24 obese men given 25 mg for 8 weeks, an oral glucose tolerance test showed impaired glucose handling at 2 and 8 weeks [9].

FDA's concern is class-wide: by raising growth hormone and IGF-1, the drug may carry the risks listed on approved growth hormone labels, including glucose intolerance and diabetes, fluid retention, intracranial hypertension, neoplasm and pancreatitis. FDA also notes that higher IGF-1 appears linked to cancer risk across ages, and that there are no long-term safety data in the older adults MK-677 is marketed to [5].

Other events reported in trials

In the 68-child LUM-201 trial, increased appetite was the most common drug-related event and occurred 2.5 to 3 times more often than with placebo [5]. The 65-adult trial recorded transient mild leg edema and muscle pain as the most frequent side effects [3]. Liver enzyme rises to 1.5 to 4 times normal, reversible, occurred in some trials, and raised prolactin has been reported [5]. Through October 1, 2023 FDA's adverse-event database held three reports for ibutamoren, including a 68-year-old man with a prior pulmonary embolism and cardiac stent who had a large intracranial infarct while taking it, confounded by other medicines [5][10].

Thymosin Alpha-1: A Quieter Record, With Less of It

FDA searched its adverse-event database on April 22, 2024 and found zero reports for thymosin alpha-1 [4]. Authors tied to the manufacturer report more than 4,400 people enrolled in trials and more than 17 million doses of Zadaxin given after marketing, with adverse experiences 'infrequent and mild'; treat that as company-linked data [4].

A 2026 Cochrane review of 10 randomized trials in 1,349 adults with chronic hepatitis B found that thymosin alpha-1 may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious adverse events (RR 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [11]. Those comparisons were against placebo, no treatment or the same co-treatment in people with hepatitis B, not in healthy adults using it for other reasons.

The practical cautions come from the Italian Zadaxin label, as summarized by FDA: it is contraindicated in pregnancy and breastfeeding, and it advises caution in people with allergies or autoimmune disease and with other immune-modulating drugs [4]. Separately, FDA's compounding page records its own concerns about the peptide as a compounded product: 'significant risk for immunogenicity for certain routes of administration', peptide-impurity and characterization problems, and safety information that is 'inadequate for the agency to sufficiently understand the extent of any safety issues' [1].

Does Either Compound Change the Other?

FDA's review of MK-677 reports no formal drug-interaction studies [5]. The most substantial controlled combination study paired MK-677 with alendronate in postmenopausal women with osteoporosis: 292 women took MK-677 25 mg plus alendronate 10 mg, alendronate alone, MK-677 alone, or placebo for 12 months. MK-677 partly offset alendronate's fall in bone-turnover markers and raised femoral neck bone density 4.2% versus 2.5% with alendronate alone, with no extra gain at the spine, total hip or total body; 8.6% of women across all four arms stopped for adverse events judged treatment-related [12][5].

Thymosin alpha-1 has been studied in combination with other drugs, such as interferon in hepatitis B [13], but those studies did not include MK-677. The Italian label cautions about combining thymosin alpha-1 with other immune-modulating drugs [4]. No study on this page describes what happens when a ghrelin-receptor agonist that raises IGF-1 is given alongside a T-cell modulator.

What the Trials Measured

Across the trials above, reported measures included IGF-1, glucose or HbA1c, liver enzymes, blood pressure, body weight and edema, depending on the study and the population [5][3][6][8]. These studies do not establish a standard monitoring schedule for people using the two compounds together, so any specific interval would be a guess rather than a standard.

What the trials show: glucose rose in several adult studies, while the short pediatric study reported no change in glucose; HbA1c rose in the hip-fracture and Alzheimer's studies [3][6][8][15]. IGF-1 rose by 39% to 84% across trials depending on population [12][6][8]. Blood pressure rose in one hip-fracture study and edema or fluid overload was more frequent in another [2][6], and liver enzymes rose in some trials [5].

For thymosin alpha-1, the FDA database search found no reports, and the Cochrane review found possibly fewer serious events than comparators in hepatitis B trials, with low-certainty evidence [4][11]. The Italian label's cautions concern who should not use it rather than laboratory values to track [4].

Regulatory Status of Both Compounds

MK-677 is not approved, and FDA's December 12, 2025 warning letter states that 'ibutamoren is excluded from the dietary supplement definition' and that products marketed with drug claims for it are 'unapproved new drugs' [16]. It sits in FDA's category 2 group of bulk substances that raise significant safety risks, and the agency's category 1 no-action policy does not apply to it [1][17]. In October 2024 FDA's Pharmacy Compounding Advisory Committee voted 1 yes to 13 no against adding ibutamoren mesylate to the pharmacy bulks list [18]. MK-677 is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [19]. WADA names ibutamoren in S2.2.4, prohibited at all times, and it stays on the 2027 List [20][21].

Thymosin alpha-1 is also not FDA-approved [4]. It is authorized as a medicine in some other countries: FDA lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people, India for chronic hepatitis B in adults with compensated liver disease, and Hong Kong, and could not verify the wider country claims in a company annual report [4]. It came off FDA's category 2 table into the 'nominated but withdrawn' table after the nominators withdrew, though FDA's immunogenicity concerns remain posted [1]; it appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians, and in category 3 for outsourcing facilities [22][23]. In December 2024 the advisory committee voted 4 yes to 17 no against adding it to the bulks list [24]. WADA does not name thymosin alpha-1; it names thymosin-beta-4 and derivatives such as TB-500, a different peptide [20][4].